Blackwell Kimberly 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Jan 5, 2022
Insider Transaction Report
Form 4
Blackwell Kimberly
Director
Transactions
- Exercise/Conversion
Common Stock
2022-01-03$47.80/sh+1,000$47,800→ 6,000 total - Sale
Common Stock
2022-01-03$83.74/sh−1,000$83,740→ 5,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-01-03−1,000→ 38,000 totalExercise: $47.80Exp: 2030-06-30→ Common Stock (1,000 underlying)
Footnotes (2)
- [F1]The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2021.
- [F2]The options vest and become exercisable in substantially equal monthly installments over the 36 months following the date of grant on July 1, 2020.